SOURCE: annual_report_text (1).txt
CHUNK: 80 of 1106
SIZE: 570 characters
PREVIOUS: chunk_0079_annual_report_text (1).txt
NEXT: chunk_0081_annual_report_text (1).txt
------------------------------
era is working on developing 
actinium-225-based radiopharmaceuticals to treat a variety 
of cancers, including prostate cancer and multiple myeloma. IBA SUPPORTS THE 
ONCIDIUM FOUNDATION
The Oncidium Foundation is a non-profit organization 
dedicated to advancing access to radioligand therapies 
in underprivileged communities worldwide through 
various initiatives, including educational programs, the 
creation of a worldwide community focused on supporting 
patients and the support of research programs. More information on Oncidium: 20
IBA
CORPORATE BROCHURE 2024